Skip to main content
SpringerLink
Log in

Tiotropium Bromide in Children and Adolescents with Asthma

  • Leading Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from the addition of this medication to their daily asthma regimen. This review discusses recent evidence on the safety and efficacy of tiotropium bromide in the management of asthma in children and adolescents. Current data support that tiotropium bromide has a bronchodilator effect, as evident by improvements in acute lung function compared with placebo; however, data are not yet available to present a stepwise approach or identify phenotypes that would benefit from the addition of tiotropium bromide. Well-designed studies are needed to compare the different step-up options to tiotropium bromide and provide an evidence-based stepwise approach for the management of asthma in children. Furthermore, study design should include identification of phenotypes that might experience a better clinical response to tiotropium bromide compared with other adjunct medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity and chronic health conditions among children and youth. JAMA. 2010;303(7):623–30.

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. 2014 National Health Interview Survey (NHIS) Data. Table 3-1, current asthma population estimates—in thousands by age, United States. https://www.cdc.gov/asthma/nhis/2014/table3-1.htm. Accessed June 2017.

  3. Schmier JK, Manjunath R, Halpern MT, et al. The impact of inadequately controlled asthma in urban children on quality of life and productivity. Ann Allergy Asthma Immunol. 2007;98(3):245–51.

    Article  PubMed  Google Scholar 

  4. Raissy HH, Kelly HW. Inhaled corticosteroids: the last 5 years. Clin Investig. 2013;3(6):595–602.

    Article  CAS  Google Scholar 

  5. National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Full Report of the Expert Panel: Guidelines for the diagnosis and management of asthma (EPR-3) 2007. https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report. Accessed June 2017.

  6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed Aug 2017.

  7. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;1:CD011721.

    Google Scholar 

  8. Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015;8:CD011397. doi:10.1002/14651858.CD011397.pub2.

    Google Scholar 

  9. Evans DJ, Kew KM, Anderson DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database Syst Rev. 2015;7:CD011437. doi:10.1002/14651858.CD011437.pub2.

    Google Scholar 

  10. Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;6:CD011438. doi:10.1002/14651858.CD011438.pub2.

    Google Scholar 

  11. SPIRIVA® RESPIMAT® (tiotropium bromide) inhalation spray, for oral inhalation [prescribing information]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2017. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdf. Accessed June 2017.

  12. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:297–304.

    Article  CAS  PubMed  Google Scholar 

  13. Radovanovic D, Santus P, Blasi F, Mantero M. Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12:17. doi:10.1186/s40248-017-0099-y.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Vogelberg C, Moroni-Zentgraf P, Leonaviciute-klimantaviciene M, et al. A randomized dose-ranging study of tiotropium respimat in children with symptomatic asthma despite inhaled corticosteroids. Resp Res. 2015;16:20.

    Article  CAS  Google Scholar 

  15. Szefler SJ, Murphy K, Harper T, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;. doi:10.1016/j.jaci.2017.01.014 (Epub 9 Feb 2017).

    Google Scholar 

  16. Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomized dose-ranging study. Respir Med. 2014;108(9):1268–76.

    Article  PubMed  Google Scholar 

  17. Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescent with moderate asthma: a 1 year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441.e8–450.e8.

    Article  Google Scholar 

  18. Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomized controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1).

  19. Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;11:CD007949.

    Google Scholar 

  20. Stempel DA, Szefler SJ, Pedersen S, VESTRI Investigators, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med. 2016;375:840–9.

    Article  CAS  PubMed  Google Scholar 

  21. Lemanske RF Jr, Mauger DT, Sorkness CA, Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362(11):975–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, MSC10 5590, Clinical and Translational Science Center, University of New Mexico, School of Medicine, 1 University of New Mexico, Albuquerque, NM, 87131, USA

    Hengameh H. Raissy

  2. Pediatrics UNMHSC, 9828 Guadalupe Trail NW, Albuquerque, NM, 87114-2009, USA

    H. William Kelly

Authors
  1. Hengameh H. Raissy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. William Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hengameh H. Raissy.

Ethics declarations

Funding

H. H. Raissy and H. W. Kelly have received no financial assistance for the preparation of this manuscript.

Conflicts of interest

H. H. Raissy is the principal investigator of AsthmaNet at the University of New Mexico, which has received drugs from GlaxoSmithKline and Merck for use in clinical trials. H. W. Kelly has received remuneration for work on the steering committees for the FDA-mandated safety trials of ICS/LABA combinations for GlaxoSmithKline, AstraZeneca, Merck, and Novartis and for acting in an advisory capacity for GlaxoSmithKline for their FDA submission of a new ICS/LABA combination. He is a member of AsthmaNet, which has received drugs from GlaxoSmithKline, Merck, Sunovion, Teva, and Boehringer Ingelheim for use in clinical trials.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raissy, H.H., Kelly, H.W. Tiotropium Bromide in Children and Adolescents with Asthma. Pediatr Drugs 19, 533–538 (2017). https://doi.org/10.1007/s40272-017-0258-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-017-0258-9

Search

Navigation